Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $90.10 | Total: $450.50 |
| 1 | 10 | $76.32 | Total: $763.20 |
| 1 | 25 | $64.66 | Total: $1,616.50 |
| 1 | 50 | $55.12 | Total: $2,756.00 |
| 1 | 100 | $47.70 | Total: $4,770.00 |
Overview
ABR-238901 is an oral, active S100A8A9 blocker that inhibits the interaction of S100A8A9 with its receptors RAGE(receptor for advanced glycation end products) and TLR4 (toll-like receptor 4). ABR-238901 has potential as a compound for the treatment of myocardial infarction (MI).
Chemical Properties
| Molecular Formula | C11H9BrClN3O4S |
| Molecular Weight | 394.63 |
| CAS Numbers | 1638200-22-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | COc1ncc(cc1Br)S(=O)(=O)Nc1cncc(Cl)c1O |
Storage and Handling
0C Short Term, -20C Long Term
References
Kim De Veirman, et al. Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion. Cancer Immunol Res. 2017 Oct;5[10] 839-846.